A2475112
Cilostazol , ≥99% , 73963-72-1
Synonym(s):
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone;Cilostazol;OPC 13013;OPC 21;Pletaal
CAS NO.：73963-72-1
Empirical Formula: C20H27N5O2
Molecular Weight: 369.46
MDL number: MFCD00866780
EINECS: 689-122-9
| Pack Size | Price | Stock | Quantity |
| 250MG | RMB40.00 | In Stock |
|
| 1G | RMB49.60 | In Stock |
|
| 5G | RMB131.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 159-160°C |
| Boiling point: | 499.57°C (rough estimate) |
| Density | 1.1832 (rough estimate) |
| refractive index | 1.7600 (estimate) |
| storage temp. | Inert atmosphere,Room Temperature |
| solubility | DMSO: 18 mg/mL, soluble |
| form | solid |
| pka | 14.22±0.20(Predicted) |
| color | off-white |
| λmax | 257nm(MeOH)(lit.) |
| Merck | 14,2277 |
| Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months |
| InChIKey | RRGUKTPIGVIEKM-UHFFFAOYSA-N |
Description and Uses
Cilostazol is a platelet aggregation inhibitor with cerebral vasodilating activity, indicated for use in stroke and myocardial infarction. In patients with cerebral thrombosis, transient ischemia and cerebral arteriosclerosis, cilostazol significantly inhibits ADP-, collagenand epinephrine-induced platelet aggregation. Side effects include headache and tachycardia.
An inhibitor of phosphodiesterase III
Safety
| Symbol(GHS) |  GHS08 |
| Signal word | Warning |
| Hazard statements | H361d |
| Precautionary statements | P201-P202-P280-P308+P313-P405-P501 |
| Hazard Codes | Xi |
| WGK Germany | 2 |
| RTECS | VC8277500 |
| HS Code | 29339900 |
| Toxicity | LD50 in mice, rats (mg/kg): >2000, >2000 i.p.; >5000, >5000 orally (Nomura) |
